Share on StockTwits

Hospira (NYSE:HSP) CFO Thomas E. Werner sold 10,000 shares of the company’s stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $51.50, for a total transaction of $515,000.00. Following the transaction, the chief financial officer now directly owns 54,614 shares in the company, valued at approximately $2,812,621. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Hospira (NYSE:HSP) traded down 0.41% on Wednesday, hitting $50.54. The stock had a trading volume of 743,271 shares. Hospira has a 52 week low of $38.11 and a 52 week high of $53.16. The stock’s 50-day moving average is $50.93 and its 200-day moving average is $45.63. The company has a market cap of $8.447 billion and a price-to-earnings ratio of 62.50.

Hospira (NYSE:HSP) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.49 by $0.11. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the company posted $0.52 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. On average, analysts predict that Hospira will post $2.20 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on HSP shares. Analysts at Wells Fargo & Co. initiated coverage on shares of Hospira in a research note on Wednesday, June 11th. They set a “market perform” rating on the stock. Separately, analysts at Zacks upgraded shares of Hospira from a “neutral” rating to an “outperform” rating in a research note on Thursday, May 29th. They now have a $58.00 price target on the stock. Finally, analysts at Leerink Swann reiterated a “market perform” rating on shares of Hospira in a research note on Thursday, May 1st. They now have a $48.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Hospira has a consensus rating of “Hold” and a consensus price target of $45.50.

Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.